Creo Medical Group plc has reported 50% revenue growth to £6m (FY24: £4m) for the year ended 31st December 2025.

The Cardiff-based medical device company, which is focused on minimally invasive surgical endoscopy for pre-cancer and cancer patients, also reported a 20% reduction in underlying operating costs to £18.4m (FY24: £23.8m).

Underlying operating loss reduced by more than 40% to £13.3m (FY24: £22.3m).